Vera Therapeutics, Inc. (VERA)


+0.35 (+4.91%)
Symbol VERA
Price $7.48
Beta 0.000
Volume Avg. 0.89M
Market Cap 329.765M
Shares () -
52 Week Range 5.2-24.94
1y Target Est -
DCF Unlevered VERA DCF ->
DCF Levered VERA LDCF ->
ROE -68.14% Strong Sell
ROA -55.92% Strong Sell
Operating Margin -
Debt / Equity 24.26% Neutral
P/E -2.41 Sell
P/B 1.93 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest VERA news

Dr. Marshall Fordyce M.D.
NASDAQ Global Market

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.